Associate Director / Director, In Vitro Pharmacology
Gordian finds targets differently. Our in vivo screens test hundreds of genes at once, directly in diseased animals, and they are producing novel targets in heart failure, kidney disease and obesity. Now we are building a new small molecule engine to drug them, and we need the biologist who makes it run.
As our Head of In Vitro Pharmacology, you will be Gordian’s first biologist drug hunter. You will build the first assays yourself, choose the hit-finding strategy and own the screening cascades that decide which chemistry moves forward, alongside our medicinal chemistry lead. As targets multiply, you will build and lead the team. A wave of new targets are coming. Are you ready for the challenge?
Journey + Destination:
Gordian Biotechnology is a therapeutics company designed as a machine that systematically
reveals the right way to cure age-related diseases: a machine for creating time.
To do that, we built Mosaic Screening, which makes causal validation both grounded in human
pathophysiology and radically more scalable in living diseased tissue. It lets us measure the causal effects of hundreds of perturbations directly in vivo, which reveals therapeutic maxima across vast target spaces (more details on our website and in our preprint). The machine is already producing wins: across six disease areas, we have mapped nearly as many targets as the field reported in 20 years, advanced a novel osteoarthritis candidate into IND-enabling studies, and started an obesity drug-discovery collaboration with Pfizer.
But there are still many diseases left to cure, and expanding the machine to tackle them starts with its most important resource: its people and culture. We work as a team, using clear goals, open communication, and direct feedback to make autonomous decisions with the bigger picture in mind. We aim for extraordinary outcomes, continually improving how we work and acting on what will create the most progress, even in unknown territory. We have deliberately designed an environment to sustain that standard: few standing meetings, hands-on experimentation and pre-mortems, weekly team lunches, and unlimited vacation that people are encouraged to use. You can dive deeper into our culture here.
This way of working has been crucial to Gordian’s success. In this role, you will help turn the targets the machine produces into small molecule medicines.
The Role:
Reporting to our VP of Biology & Pharmacology and working as a peer to our medicinal chemists, your mission is to make three things work across our obesity, kidney (CKD/DKD) and heart failure (HFpEF) programs:
- Build assays for novel targets. Most of our targets have no tool compounds, no off-the-shelf assay and incomplete pathway biology. You will design, develop and validate the biochemical, biophysical and cell-based assays to establish target biology and enable small molecule program. Define assay performance criteria, controls, and reproducibility standards, ensuring assays are biologically relevant, mechanistically informative, and fit for purpose across screening and compound characterization. Develop orthogonal approaches where needed to confirm findings and address assay limitations.
- Own hit finding and the screening cascade. For each small molecule program, through the collaboration with experienced medicinal chemists, you will choose the hit-finding strategy (HTS, fragment, DEL, or multiple approaches in parallel), design the cascade from hit identification through lead optimization, set the progression criteria with the Chemistry and Biology teams, and keep data flowing on a cadence that drives design-make-test cycles. Integrate SAR, functional, and mechanistic data to test hypotheses, characterize MoA and resolve critical program uncertainties. Provide scientific recommendations on compound progression and program go/no-go decisions through candidate selection.
- Build the in vitro drug discovery engine as targets grow. Most screening, selectivity and profiling will run at CROs; you choose them, transfer assays to them and look under the hood at every one. Establish expectations for CRO performance, study design, timelines, budgets, and quality standards, while maintaining critical scientific oversight of external work. As the pipeline expands beyond 3 active discovery targets, build and develop internal biology capabilities, recruit key talent, work with the VP of Biology & Pharmacology to prioritize resources, timelines, and budgets across programs.
This is a leadership role that you will start from the bench. You are the first (of many) dedicated drug discovery biology hires. In the first year, at least half of your time is hands-on assay development and execution in our lab, especially for new-target assays. The rest is cascade design, CRO management, data analysis and communication. The bench time is how you earn the credibility to set the standard for in vitro data at Gordian. This will put you in the best position to grow the team and make real drugs for diseases of unmet need.
In your first month, learn Gordian’s platform well enough to explain it unaided to an external partner; get up to speed on the target validation packages and status of our obesity, CKD/DKD and HFpEF programs and our active small molecule work; audit our existing in vitro assays and CRO data; and write an assay plan for your first novel target, including the recommended hit-finding approach, with our Chemistry and Biology leads.
By two months, you will have personally developed and validated the first novel-target assay in our lab, with a validation report and an SOP another scientist can follow. Your first CRO study will be launched, with you owning vendor selection, scope and data acceptance criteria, and you will have agreed with our ex vivo team and disease lead on the human system, readouts and proof-of-mechanism criteria for your first target.
By three months, the screening cascade for your first program, including progression criteria, will be agreed with Chemistry and Biology team, your first SAR data set will be in Chemistry’s hands, and the plan for counter-screens and orthogonal assays will be set.
By six months, you will have two or more validated primary assays for novel targets, a full cascade running for at least one program with a steady 1-2 week turnaround, and hit triage complete for your first novel-target screen, with artifacts and false positives removed and confirmed hit series in Chemistry’s hands.
By twelve months, your in vitro data package will support a lead optimization or no-go decision for at least one program, and you will have brought a new in vitro capability online. Over time, you will build the team and the data packages that carry Gordian’s targets to development candidates.
And you:
You have a track record of success in high-agency work, consistently creating momentum rather than waiting for direction.
You set scientific priorities on your own, decide where time and budget go across competing programs, and are accountable for the results.
You want to do your best work alongside exceptional teammates and are energized by environments where people push each other to think more clearly, work at a higher standard, and grow into better versions of themselves.
You truly want to play a key role in an early-stage startup turning novel targets into medicine and cure diseases of aging: a fast-paced environment full of both uncertainty and new challenges, demanding relentless resourcefulness.
You have taken small molecule programs the distance. You have a Ph.D. in pharmacology, biochemistry, cell biology, physiology or a related field and 12+ years in industry small molecule drug discovery across multiple programs (an M.S. with 16+ years of directly relevant industry experience will also be considered). You have designed and owned screening cascades for multiple programs and taken at least one from primary screen through lead optimization, and your experience includes cardiometabolic, renal or cardiovascular drug discovery. You have hired, mentored and developed high-performing scientists, and you can show how the capabilities you built made drug discovery measurably faster or better.
You know the modern hit-finding toolkit. You have hands-on experience with at least two of the following: HTS using ASMS/SPR/RapidFire, fragment-based screening, DEL screening. You know which fits a given target and what each needs from the assay, and have set up or adapted assays for fragment or DEL campaigns and triaged the hits afterwards.
You have built assays for targets no one has drugged before. You have developed assays from scratch for poorly characterized targets with no tool compounds or established readouts.
You understand in vitro pharmacology from first principles. You can explain affinity versus potency versus efficacy, why an EC50 or IC50 shifts with substrate or agonist concentration, receptor reserve or cell background, and how competitive, allosteric, tight-binding and time-dependent mechanisms show up in your data. You read curve shapes correctly and can bridge biochemical, cellular and tissue potency. You understand the target, pathway and disease biology behind your assays, including target engagement and mechanism of action, and you notice when a result does not fit known biology or physiology.
You know how assays work, and how they fail. You understand how common formats generate signal — TR-FRET/HTRF, AlphaLISA, luminescence, fluorescence polarization, SPR, radioligand binding, reporter and high-content imaging — validate to statistical standards (Z′, MSR), and recognize compound artifacts such as aggregation, interference and cytotoxicity. You know which counter-screens each format needs and have triaged false positives out of a real hit list. You know the limits of each experimental model and can tell a real biological effect from normal variability. When data conflict, you find the knowledge gap, design the experiment that answers it most efficiently, and make a clear recommendation.
You are a true partner to chemistry. You have worked with medicinal chemists on SAR, can show how your data changed compound design, and understand chemistry well enough to challenge compound decisions. Beyond chemistry, you challenge assumptions, influence cross-functional decisions, and explain complex findings clearly to team leadership.
You have scoped and managed CRO studies, transferred assays with bridging data, and caught and corrected external data-quality problems. You analyze data rigorously (e.g., GraphPad, Genedata, Spotfire; Python or R a plus) and document your work so others can find, reproduce and build on it.
Additional valuable skills if you have them
- Experience across more than one of kidney, cardiac and metabolic biology.
- First-in-class target experience, with no prior chemistry or tool compounds.
- Experience working across target classes such as GPCRs, enzymes, nuclear receptors and transporters.
- Lab automation, liquid handling or high-content imaging.
- Advanced human cell models: iPSC-derived cells, 3D cultures or organoids, engineered heart tissue, kidney organoids or microphysiological systems.
- Calcium handling and contractility assays (e.g., IonOptix).
- Understanding of PK/PD and in vitro to in vivo translation in cardiometabolic diseases.
- Experience as project leader on a small molecule program.
- Partner- or BD-facing experience presenting preclinical data.
- A peer-reviewed publication record in pharmacology or cardiometabolic biology.
The Details:
This is an onsite role in South San Francisco because hands-on lab work is central to it. Gordian offers meaningful equity, a competitive salary, full health, dental, vision, and life insurance, a 401(k) with match, onsite lunch three days a week, an onsite gym, an unlimited vacation policy, and access to world-class mentors and advisors.
The pay range for this role is:
170,000 - 250,000 USD per year (South San Francisco)
Assets
South San Francisco, CA
Share on: